DeepMed Research

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Sequential Analysis in Patients With an Hemopathy

Not Applicable

Recruiting

Conditions: Hemopathy

Interventions: Other: Blood samples

First Posted Date: 2014-10-09

Last Posted Date: 2017-08-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 246

Registration Number: NCT02260739

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress

Phase 3

Completed

Conditions: ENT Cancer

Interventions: Drug: Escitalopram
Other: Placebo

First Posted Date: 2014-09-22

Last Posted Date: 2016-06-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 38

Registration Number: NCT02246244

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

Phase 2

Conditions: Diffuse Intrinsic Pontine Glioma

Interventions: Drug: Erlotinib
Drug: Everolimus
Drug: Dasatinib

First Posted Date: 2014-09-08

Last Posted Date: 2018-07-23

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 250

Registration Number: NCT02233049

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Phase 2

Completed

Conditions: Pancreatic Neuroendocrine Carcinoma

Interventions: Drug: Sunitinib
Drug: 177Lu-DOTA0-Tyr3-Octreotate

First Posted Date: 2014-09-03

Last Posted Date: 2025-04-20

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 84

Registration Number: NCT02230176

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors

Phase 1

Completed

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: Bortezomib

First Posted Date: 2014-08-19

Last Posted Date: 2016-03-25

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 18

Registration Number: NCT02220049

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma

Phase 1

Completed

Conditions: Primary Peritoneal Carcinoma
Ovarian Adenocarcinoma
Fallopian Tube Adenocarcinoma

Interventions: Drug: Cisplatin
Drug: Bevacizumab

First Posted Date: 2014-08-15

Last Posted Date: 2016-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 30

Registration Number: NCT02217956

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors

Phase 1

Conditions: Patients With Advanced or Metastatic Solid Tumors

Interventions: Drug: Cetuximab
Drug: Temsirolimus

First Posted Date: 2014-08-13

Last Posted Date: 2016-02-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 42

Registration Number: NCT02215720

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val de Marne, France

Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma

Phase 2

Completed

Conditions: Uterus Leiomyosarcoma
Soft Tissue Leiomyosarcoma

Interventions: Drug: Doxorubicin
Drug: Trabectedin

First Posted Date: 2014-05-06

Last Posted Date: 2017-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 110

Registration Number: NCT02131480

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors

Phase 2

Conditions: Non-seminomatous Germ-cell Tumors

Interventions: Drug: Cabazitaxel

First Posted Date: 2014-04-15

Last Posted Date: 2016-06-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 34

Registration Number: NCT02115165

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

Not Applicable

Conditions: Melanoma
Non Small Cell Lung Cancer
Small Cell Lung Cancer

Interventions: Procedure: Blood sample
Procedure: Tumorous biopsy
Procedure: Healthy material sample

First Posted Date: 2014-04-07

Last Posted Date: 2016-06-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 2200

Registration Number: NCT02105168

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy